Elafibranor

Recent advancements have been made in the treatment of primary biliary cholangitis, particularly for patients who do not respond adequately to first-line treatment.

PHILADELPHIA — Iqirvo demonstrated significant biochemical response and alkaline phosphatase normalization in patients with both early- and advanced-stage primary biliary cholangitis, according to late-breaking data presented here.

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.